Altamira Therapeutics Ltd. Increase Decrease In Net Defined Benefit Liability Asset Resulting From Expense Income In Profit Or Loss
Altamira Therapeutics Ltd. (CYTOF) reported Increase Decrease In Net Defined Benefit Liability Asset Resulting From Expense Income In Profit Or Loss of $208.54 thousand for the 12-month period ending 2024-12-31, per its 20-F filed 2025-04-30.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromExpenseIncomeInProfitOrLoss · last filed 2025-04-30
| Period end | Increase Decrease In Net Defined Benefit Liability Asset Resulting From Expense Income In Profit Or Loss 12 month |
|---|---|
| 2024-12-31 | $208.54K 20-F · filed 2025-04-30 |
| 2023-12-31 | $191.94K 20-F · filed 2025-04-30 |
| 2022-12-31 | $275.69K 20-F · filed 2025-04-30 |